Inventing cutting-edge therapeutics
for the treatment of cancer

Fostering a culture grounded in our vision, mission, and values, CytomX is a leading clinical-stage biopharmaceutical company in the growing field of conditional activation with a team that is dedicated to pioneering bold science to make a difference. CytomX has multiple Probody® therapeutics in the clinic and in earlier phases of preclinical research. Our goal is to reinvent biologic therapeutics to destroy cancer, differently.

Learn More

Yes, we can truly make a difference in the lives of patients.

We’re on it.

Read More

Vision

Transforming lives with safer, more effective therapies

Mission

Changing the treatment of cancer by urgently advancing our Probody® pipeline

Values

Integrity

We act in an honest, respectful, ethical manner

Commitment

We are dedicated to patients, CytomX, and our teammates

Creativity

Curiosity and innovation have the power to change lives

Teamwork

Together, we will succeed

Accountability

Through open communication, we hold each other to the highest possible standards

Fun

We enjoy working together and celebrating success

Our executive team

CytomX is led by a seasoned executive team with deep experience in the fields of biologic therapeutics development, cancer biology, clinical and translational medicine and business development.

Sean A. McCarthy
D.Phil.

Chief Executive Officer and Chairman

Marcia P. Belvin
Ph.D.

SVP, Head of Research

Jeff Landau

SVP, Head of Strategy and Chief Business Officer

Jamie Moore
Ph.D.

SVP, Head of Protein and Process Sciences and Manufacturing

Chris Ogden

SVP, Finance and Accounting

Danielle Olander-Moghadassian

SVP, Chief Human Resources Officer

Leslie Robbins
J.D.

SVP, Intellectual Property

Lloyd A. Rowland, Jr.
J.D.

SVP, General Counsel, Secretary
and Chief Compliance Officer

Sean A. McCarthy
D.Phil.

Chief Executive Officer and Chairman

Dr. McCarthy joined CytomX in 2010 as the chief business officer, served as the chief executive officer (CEO) since 2011, and has been the CEO and chairman since 2019. Previously, Dr. McCarthy was a transactional partner at Pappas Ventures. Prior to Pappas, Sean headed business development and strategy at SGX Pharmaceuticals, a structure-based drug discovery company focused on oncology. Earlier in his career he served in various research and development roles at Millennium Pharmaceuticals. Dr. McCarthy is an author on multiple peer-reviewed scientific publications and issued patents. He is a member of the board of directors of Oncoresponse, Inc. and a member of the board of directors and executive committee of California Life Sciences. Dr. McCarthy received his B.S. degree in biochemistry and pharmacology at King’s College, University of London. He also received an M.B.A. from the Rady School of Management at UCSD and a DPhil in cancer biology from St. John’s College, University of Oxford.

Marcia P. Belvin
Ph.D.

SVP, Head of Research

Dr. Belvin joined CytomX in 2018. Prior to this, Dr. Belvin held roles of increasing responsibility at Genentech where, for over 13 years, she led multiple preclinical pipeline teams and oversaw programs in cancer signaling, cancer metabolism, and cancer immunology. Dr. Belvin began her career at Exelixis where she managed teams responsible for preclinical pipeline discovery within the oncology and inflammation portfolios. Dr. Belvin received her B.A. degree from Harvard University and her Ph.D. from the University of California, Berkeley. Dr. Belvin also trained at the Dana-Farber Cancer Institute and Cold Spring Harbor Laboratory.

Jeff Landau

SVP, Head of Strategy and Chief Business Officer

Mr. Landau has over 20 years of biopharmaceutical experience in corporate development, corporate strategy, and new product strategy and planning. Most recently, Mr. Landau was senior vice president of corporate development, commercial, and new product strategy at Catalyst Biosciences, Inc. Additionally, he was a member of the Catalyst Biosciences executive management team responsible for partnering, license & acquisition, corporate strategy, pipeline and new product planning, alliance and project management. Prior to joining Catalyst, Mr. Landau held corporate development and global product and pipeline strategy roles of increasing responsibility at Threshold Pharmaceuticals and Onyx Pharmaceuticals (acquired by Amgen). Mr. Landau received his M.B.A. from Stanford Graduate School of Business and his B.S. with honors in biochemistry/biotechnology from Virginia Polytechnic Institute.

Jamie Moore
Ph.D.

SVP, Head of Protein and Process Sciences and Manufacturing

Dr. Moore joined CytomX in 2021 as the Senior Vice President of Protein and Process Sciences and Manufacturing. Previously Dr. Moore worked at Genentech for 20 years, most recently serving as the vice president of manufacturing science and technology for commercial products.  In this capacity, she provided technical leadership in support of the life-cycle management for Roche commercial biologics and small molecule products. She started her career at Genentech in 1995 as a quality control scientist. She then pursued her PhD in 1999 from UCSF in chemistry and chemical biology and and returned to Genentech in 2004. Dr. Moore held multiple technical and managerial leadership roles within the process development organization including senior director and head of US pharmaceutical development, and director of early and late stage pharmaceutical development. Externally, she serves on the Board of Directors for CASSS and participates on the CMC Strategy planning committee.

Chris Ogden

SVP, Finance and Accounting

Mr. Ogden joined CytomX in August of 2021 after a 16-year tenure at Eli Lilly and Company where he held senior financial leadership positions including most recently as chief financial officer of Lilly Diabetes.  Prior to his role in Lilly Diabetes, Mr. Ogden was the chief financial officer and treasurer of Lilly del Caribe in Puerto Rico.  Over the course of his career at Eli Lilly, Mr. Ogden held financial leadership roles that included drug development, manufacturing, commercial operations, and investor relations.  Mr. Ogden received his M.B.A. from Harvard Business School and his B.A. in economics from Wabash College. 

Danielle Olander-Moghadassian

SVP, Chief Human Resources Officer

Danielle Olander-Moghadassian joined CytomX in 2014, and serves as senior vice president of talent and systems development.  She is accountable for optimizing talent, bringing organizational systems to life, and helping the organization to achieve our mission, vision, and values. As an industry innovator, she has developed a strategic plan that includes the creation of a system for aligning corporate goals with business strategy that has resulted in significant growth, scalability, and sustainability at CytomX.  Danielle leads the following functions for the organization: human resources, information technology, facilities, and administration. Prior to CytomX, Danielle held leadership positions at Portola Pharmaceuticals, SuperGen (now Astex Pharmaceuticals), SUGEN (acquired by Pfizer), and Kinetic Search.  She received her B.S. in human resource management from Colorado Technical University.

Leslie Robbins
J.D.

SVP, Intellectual Property

Leslie Robbins joined CytomX in February 2019 as senior vice president of intellectual property. Ms. Robbins brings more than 25 years of legal experience in the biotechnology industry to CytomX. Most recently, Ms. Robbins was vice president of intellectual property at Coherus BioSciences, a biosimilars company. Prior to that, she held intellectual property roles at Onyx Pharmaceuticals (acquired by Amgen) and Elan Pharmaceuticals. Ms. Robbins began her legal career at a boutique patent firm. Prior to law school, Ms. Robbins was a research associate at Chiron Corporation.

Ms. Robbins received a J.D. from the Chicago-Kent College of Law at the Illinois Institute of Technology and a bachelor’s degree in microbiology and immunology from the University of California, Berkeley.

Lloyd A. Rowland, Jr.
J.D.

SVP, General Counsel, Secretary
and Chief Compliance Officer

Lloyd Rowland, Jr. joined CytomX in May 2018 as senior vice president, general counsel, secretary, and chief compliance officer. Mr. Rowland brings 25 years of biotechnology and pharmaceutical industry legal counsel and transactional experience to CytomX. Most recently, Mr. Rowland held the position of senior vice president, general counsel and chief compliance officer of Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Prior to this, Mr. Rowland held various roles at Amylin Pharmaceuticals throughout his twelve-year career, most recently as vice president and chief compliance officer and previously, as vice president, general counsel and secretary. During his time as general counsel at Amylin, he directed all corporate legal and compliance affairs for the company including the launch of two pharmaceutical products. Prior to joining Amylin, Mr. Rowland served as vice president, secretary and general counsel for Alliance Pharmaceutical Corp. Mr. Rowland received his B.S. degree in economics and political science from Southern Methodist University, and his J.D. from Emory University School of Law.

Board of directors

Sean A. McCarthy
D.Phil.

Chief Executive Officer and Chairman

READ BIO

Sean A. McCarthy
D.Phil.

Chief Executive Officer and Chairman

Dr. McCarthy joined CytomX in 2010 as the chief business officer, served as the chief executive officer (CEO) since 2011, and has been the CEO and chairman since 2019. Previously, Dr. McCarthy was a transactional partner at Pappas Ventures. Prior to Pappas, Sean headed business development and strategy at SGX Pharmaceuticals, a structure-based drug discovery company focused on oncology. Earlier in his career he served in various research and development roles at Millennium Pharmaceuticals. Dr. McCarthy is an author on multiple peer-reviewed scientific publications and issued patents. He is a member of the board of directors of Oncoresponse, Inc. and a member of the board of directors and executive committee of California Life Sciences. Dr. McCarthy received his B.S. degree in biochemistry and pharmacology at King’s College, University of London. He also received an M.B.A. from the Rady School of Management at UCSD and a DPhil in cancer biology from St. John’s College, University of Oxford.

Alan Ashworth
Ph.D., FRS

Director

READ BIO

Alan Ashworth
Ph.D., FRS

Director

Dr. Ashworth is a world-renowned expert in cancer research and a global leader in cancer therapy development. He serves in multitude of roles, including as the president of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center; senior vice president for cancer services at UCSF Health; a professor of medicine within the division of hematology/oncology, department of medicine; and  the E. Dixon Heise Distinguished Professor in Oncology. Previously, Dr. Ashworth was chief executive officer of the Institute of Cancer Research and director of the Breakthrough Breast Cancer Center in London, U.K. He is an elected member of the European Molecular Biology Organization, the Academy of Medical Sciences, and a Fellow of the Royal Society. Dr. Ashworth has received a number of scientific prizes and awards, including the European Society of Medical Oncology Lifetime Achievement Award, the David T. Workman Memorial Award of the Samuel Waxman Cancer Research Foundation, the Meyenburg Foundation’s Cancer Research Award, the Basser Global Prize, the Genetics Society Medal, and the Susan G Komen Brinker award. Dr. Ashworth received his Ph.D. in biochemistry from University College London, U.K., and his B.Sc. in chemistry and biochemistry from Imperial College of Science and Technology, University of London, U.K.

Halley E. Gilbert

Director

READ BIO

Halley E. Gilbert

Director

Ms. Gilbert brings 20 years of operational, transactional, and strategic leadership experience within the biopharmaceutical sector to CytomX, having served in roles overseeing the transformation of companies from development to the commercial stage.  Ms. Gilbert most recently served as senior vice president, corporate development and chief administrative officer of Ironwood Pharmaceuticals, Inc. where she oversaw corporate and business development, legal, compliance and government affairs. Prior to joining Ironwood, Ms. Gilbert served as vice president, deputy general counsel at Cubist Pharmaceuticals, Inc., where she managed the legal function during the company’s first commercial launch of an acute care antibiotic. Prior to her time with Cubist, Ms. Gilbert served as corporate counsel at Genzyme Corporation. Ms. Gilbert began her career at the law firm of Skadden, Arps, Slate, Meagher & Flom LLP, where she specialized in mergers and acquisitions and securities law. Ms. Gilbert currently serves on the board of Arcutis Biotherapeutics and Vaxcyte, Inc. Ms. Gilbert received a J.D. from Northwestern University School of Law and a B.A. from Tufts University.

Elaine V. Jones
Ph.D.

Director

READ BIO

Elaine V. Jones
Ph.D.

Director

Dr. Elaine Jones served as the vice president of worldwide business development and senior partner at Pfizer Ventures, the venture capital arm of Pfizer, Inc. before retiring in 2019. As Pfizer Ventures executive director starting in 2008, Dr. Jones was responsible for making and managing venture investments for Pfizer as well as serving in Board roles for several and therapeutic companies. Prior to this, Dr. Jones held the position of general partner at EuclidSR Partners, a venture firm specializing in private investment in public equity within the health sciences, healthcare, biopharmaceutical sectors. Dr. Jones began her investing career in 1999 at S.R. One, the corporate investment fund of GlaxoSmithKline. Prior to this, Dr. Jones served as director of scientific licensing at SmithKline Beecham and as a research scientist in the research and development division of SmithKline Beecham Pharmaceutical. During her venture career, Dr. Jones has served on the boards of more than 20 early to mid-stage biotechnology, therapeutic and pharmaceutical companies. Dr. Jones currently serves as a member of the board of directors of Gritstone Oncology and NextCure. Dr. Jones holds a B.S. in biology from Juniata College and a Ph.D. in microbiology from the University of Pittsburgh.

James R. Meyers

Director

READ BIO

James R. Meyers

Director

James R. Meyers brings more than 30 years of worldwide commercial leadership experience within the biotechnology industry. Mr. Meyers served as Gilead’s executive vice president of worldwide commercial operations where he was responsible for all commercial activities including pricing and market access in North America, Europe, Middle East, Australia and Japan. Since his retirement in 2018, Mr. Meyers now serves as a senior advisor to the company. Over his 22-year career at Gilead, Mr. Meyers led some of the most important and successful product launches in the history of the biopharmaceutical industry, most notably in the therapeutic areas of HCV and HIV. Prior to joining Gilead, Mr. Meyers held positions of increasing responsibility in sales, training, marketing and management with Zeneca Pharmaceuticals and Astra USA. Mr. Meyers currently serves on the Board of Arbutus Biopharma Corporation, a public biopharmaceutical company focused on commercializing a cure for patients suffering from chronic hepatitis B infection. Mr. Meyers holds a B.S. in economics from Boston College.

Mani Mohindru
Ph.D.

Director

READ BIO

Mani Mohindru
Ph.D.

Director

Dr. Mohindru is a skilled biotech executive with several years of biopharmaceutical industry leadership, coupled with experience on Wall Street. Most recently she was the chief executive officer of CereXis, Inc., a biotech company focused on rare tumor indications. Previously, she was the chief financial officer and chief strategy officer at Cara Therapeutics (Nasdaq: CARA) and chief strategy officer at Curis, Inc. (Nasdaq: CRIS). Prior to her leadership roles in the biotechnology industry, Dr. Mohindru spent many years as an equity research analyst covering the biotechnology sector at UBS, Credit Suisse and ThinkEquity. She also co-founded a privately- held biotechnology company and was a healthcare industry consultant. Currently, she is a member of the board of directors of SAB Biotherapeutics, a clinical-stage biopharmaceutical company advancing a new class of immunotherapies. Dr. Mohindru received her Ph.D. in neurosciences from Northwestern University, her master’s degree in biotechnology, and her B.S. in human biology with honors from the All India Institute of Medical Sciences, New Delhi, India.

Matthew Young

Director

READ BIO

Matthew Young

Director

Matthew P. Young is a managing director of Longitude Capital. Prior to joining Longitude Capital in 2022, Mr. Young was the chief operating officer and chief financial officer of GRAIL, a developer of blood cancer tests that was acquired by Illumina for $8 billion in 2021. Prior to joining GRAIL in October 2019, Mr. Young served as executive vice president and chief financial officer of Jazz Pharmaceuticals – a role he held since February 2015. He served as a senior vice president and the chief financial officer of Jazz beginning in 2014 after working as the senior vice president of corporate development of Jazz since joining the company in 2013. Prior to joining Jazz, Mr. Young worked in investment banking for approximately 20 years, most recently as a managing director in global healthcare of Barclays Capital Inc., an investment banking firm, where his role included acting as the co-head of life sciences at Barclays Capital. From 2007 to 2008, Mr. Young served as a managing director of Citigroup Global Markets Inc., an investment banking firm, and from 2003 to 2007, as a managing director of Lehman Brothers Inc., an investment banking firm. In 2015, he joined the board of directors of PRA Health Sciences Inc., a contract research company. Mr. Young received a B.S. in economics and an M.B.A. from the Wharton School of the University of Pennsylvania.

Scientific advisory board

Lisa Butterfield
Ph.D.

Vice President of the Parker Institute for Cancer Immunotherapy Research Center and adjunct professor of microbiology and immunology

University of California, San Francisco

READ BIO

Lisa Butterfield
Ph.D.

Vice President of the Parker Institute for Cancer Immunotherapy Research Center and adjunct professor of microbiology and immunology

University of California, San Francisco

Lisa H. Butterfield, Ph.D., is an Adjunct Professor of Microbiology and Immunology at the University of California, San Francisco and recently served as the Vice President, Research and Development, of the Parker Research Institute for Cancer Immunotherapy.  Her research is focused on cancer vaccines and cellular therapies. Dr. Butterfield previously served as Professor of Medicine, Surgery, Immunology and Clinical and Translational Science at the University of Pittsburgh (2003-2018) and Director of the Hillman Cancer Center Immunologic Monitoring and Cellular Products Laboratory. She holds a Ph.D. in Biology from UCLA, followed by postdoctoral fellowships in Cellular Immunology and Cancer Gene Therapy also at UCLA. She is a former president of the Society of Immunotherapy of Cancer (SITC, 2017-2018) and a member of the SITC Executive Committee (2015-2020). She led the Immunology Reference Lab for the ECOG-ACRIN NCI cooperative group (2006-2018). She investigates immunotherapy for hepatocellular cancer and melanoma, involving peptides, dendritic cells and adenoviruses, and effector responses to tumor antigens. She has published over 150 peer-reviewed manuscripts, reviews and book chapters, and mentored over 20 students and postdocs.

Lisa Coussens
Ph.D.

Hildegard Lamfrom Endowed Chair in Basic Science Professor and Chairwoman of the department of cell, developmental & cancer biology, and Associate Director for basic research at the Oregon Health & Science University Knight Cancer Institute

READ BIO

Lisa Coussens
Ph.D.

Hildegard Lamfrom Endowed Chair in Basic Science Professor and Chairwoman of the department of cell, developmental & cancer biology, and Associate Director for basic research at the Oregon Health & Science University Knight Cancer Institute

Dr. Coussens is the chair of the department of cell, developmental, and cancer biology, the associate director for basic research in the Knight Cancer Institute at Oregon Health & Sciences University (OHSU), and holds the Hildegard Lamfrom chair in basic science.  She received her Ph.D. in biological chemistry from UCLA in 1993 and completed her postdoctoral fellowship in cancer biology at UCSF in Douglas Hanahans’ laboratory. Dr. Coussens’ research focus is on elucidating the roles of immune cells and their mediators as critical regulators of solid tumor development. Her lab reported that lymphocytes selectively regulate myeloid cell functions in mouse models of squamous and mammary carcinoma, mesothelioma, and pancreatic adenocarcinoma and that the selective inhibition of key factors regulating either myeloid recruitment or function significantly enhances the efficacy of chemo- and radiation therapy, thereby extending long-term survival of tumor-bearing mice. These discoveries are currently being translated into the clinical realm; Dr. Coussens is the lead PI on a KOMEN Promise grant conducting an investigator-initiated multi-center Phase Ib/II clinical trial evaluating a novel macrophage-antagonist in combination with chemotherapy in women with metastatic triple-negative breast cancer. More recently, Dr. Coussens was awarded a Stand Up to Cancer – Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research grant focused on clinical evaluation of immune-based therapies in pancreas cancer.  Her contributions to this international team are based on her laboratory’s identification of B cells and humoral immune-mediated factors regulating T cells and immune suppression in squamous and pancreas cancer.  Specifically, her studies support the evaluation of a Bruton’s tyrosine kinase (BTK) inhibitor plus chemotherapy in Phase Ib/II clinical trials of pancreatic cancer and head and neck cancer patients. Dr. Coussens has received the prestigious Gertrude B. Elion Award from the American Association of Cancer Research (AACR), the Mallinckrodt Award for Medical Science, a V Foundation Scholar Award, and two sequential Era of Hope Scholar Awards from the Department of Defense breast cancer research program.  In 2012, she was the recipient of the AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship and, in 2015, the recipient of the 13th Rosalind E. Franklin Award from the National Cancer Institute.

W. Michael Kavanaugh
M.D.

Former Chief Scientific Officer, CytomX

Attending staff physician at the San Francisco Veterans Administration Medical Center and associate clinical professor of medicine at the University of California, San Francisco

READ BIO

W. Michael Kavanaugh
M.D.

Former Chief Scientific Officer, CytomX

Attending staff physician at the San Francisco Veterans Administration Medical Center and associate clinical professor of medicine at the University of California, San Francisco

Michael Kavanaugh, M.D. joined CytomX in January 2015 and served as senior vice president, chief scientific officer, and head of research and early development until December 2020. Prior to joining CytomX, Dr. Kavanaugh was senior vice president and chief scientific officer of Five Prime Therapeutics. Since joining the company in 2009, he held multiple positions in research and development and led the growth of the company’s therapeutic pipeline. Before Five Prime, Dr. Kavanaugh served as vice president of Novartis Vaccines & Diagnostics, Inc. and executive director of oncology biologics in the Novartis Institutes of Biomedical Research. He joined Novartis in 2006 as part of the company’s acquisition of the Chiron Corporation, where he was vice president and head of antibody and protein therapeutics research. Dr. Kavanaugh received his medical doctorate from Vanderbilt University and his bachelor’s degree in molecular biochemistry and biophysics from Yale University. He completed training in internal medicine, cardiovascular disease, and molecular and cellular biology at the University of California, San Francisco and the Cardiovascular Research Institute. Dr. Kavanaugh also currently serves as an attending staff physician at the San Francisco Veterans Administration Medical Center and as an associate clinical professor of medicine at UCSF.

John Lambert
Ph.D.

Consultant and Scientific Advisor

Honorary Professor, Queen’s University Belfast, Northern Ireland, UK

READ BIO

John Lambert
Ph.D.

Consultant and Scientific Advisor

Honorary Professor, Queen’s University Belfast, Northern Ireland, UK

Dr. Lambert graduated from Christ’s College, University of Cambridge (England, UK), with a degree in natural sciences in 1972. He then earned a Ph.D. in biochemistry from the University of Cambridge in 1976, working on the structure of glycolytic enzymes under the supervision of Professor Richard N. Perham. Dr Lambert’s postdoctoral training was working on ribosome structure in the laboratory of Dr. Robert R. Traut at the University of California, Davis (1976-1980) and working on the arom multienzyme complex in the laboratory of Dr John R. Coggins at the University of Glasgow, Scotland (1980-1982). In 1982, Dr. Lambert joined the Dana-Farber Cancer Institute at Harvard Medical School, working on the ImmunoGen-funded programs to develop antibody-drug conjugates (ADCs) and immunotoxins as anti-cancer therapeutics. Dr. Lambert joined ImmunoGen in 1987 when the company established independent research laboratories in Cambridge, Massachusetts. After working in a variety of roles at the company, Dr. Lambert served as chief scientific officer from 2008 until 2015. In 2016, he became a distinguished research fellow at the company until his retirement at the end of 2017. He served on the executive committee of the company as the executive vice president of research from 2008 until 2016, followed by a year on the executive committee in an emeritus capacity until retirement. During Dr Lambert’s tenure in leadership roles at ImmunoGen, the company invented the ADC technology that resulted in the Genentech/Roche drug, Kadcyla® (approved in 2013 for treating HER2+ breast cancer), as well as numerous other ADCs taken into clinical development.  One of these is ImmunoGen’s promising drug candidate, mirvetuximab soravtansine, an ADC currently in a phase 3 trial for the treatment of platinum-resistant ovarian cancer. Dr Lambert is the author/co-author of over 120 peer-reviewed scientific publications. In 2016, Dr Lambert was elected as a fellow of the American Institute for Medical and Biological Engineering (AIMBE).  In 2018, he was appointed as an honorary professor of Queen’s University Belfast, Northern Ireland, UK.

Charles Sentman
Ph.D.

Professor of microbiology and immuniology and director of the Center for Synthetic Immunity at Dartmouth Medical School

READ BIO

Charles Sentman
Ph.D.

Professor of microbiology and immuniology and director of the Center for Synthetic Immunity at Dartmouth Medical School

Charles Sentman is a professor in the department of microbiology & immunology at the Geisel School of Medicine at Dartmouth and the director of the Center for Synthetic Immunity. Dr. Sentman’s research interests are natural killer (NK) cell recognition mechanisms, the role of NK cells as a part of the immune defense against cancer and infection, and how NK cell and T-cell effector mechanisms affect the tumor microenvironment. His laboratory is focused on the development of novel immunotherapy strategies for cancer, and there are several major areas of research: chimeric antigen receptor-based immunotherapy, bi-specific engager targeting of tumors, and development of novel signaling platforms for cell-based therapies. Earlier in his career, Dr. Sentman worked as a team leader and section leader at AstraZeneca R&D in Lund, Sweden. Dr. Sentman received a B.S. from the University of Illinois and a Ph.D. from the University of Texas Southwestern Medical Center. He completed postdoctoral training at Washington University and the Karolinska Institute.

Louis Weiner
M.D.

Professor, Francis L. & Charlotte G. Gragnani chair of oncology, director of Georgetown Lombardi Comprehensive Cancer Center, and director of the MedStar Georgetown Cancer Institute at Georgetown University Medical Center

READ BIO

Louis Weiner
M.D.

Professor, Francis L. & Charlotte G. Gragnani chair of oncology, director of Georgetown Lombardi Comprehensive Cancer Center, and director of the MedStar Georgetown Cancer Institute at Georgetown University Medical Center

Dr. Louis Weiner is director of Georgetown Lombardi Comprehensive Cancer Center, one of 49 National Cancer Institute (NCI)-designated comprehensive cancer centers in the United States. He holds the Francis L. and Charlotte G. Gragnani chair and is professor of oncology and chair of the department of oncology at Georgetown University Medical Center. He also serves as the director of the MedStar Georgetown Cancer Institute, a cancer service line serving patients in the Washington D.C. and Baltimore metropolitan areas. He is responsible for the operation and development of the cancer center, including its research, clinical, and educational missions. The clinical mission includes leading the MedStar-Georgetown Cancer Network in the metropolitan Washington area. Weiner is known for his laboratory and clinical research focusing on new therapeutic approaches that mobilize the patient’s immune system to fight cancer using monoclonal antibodies and other modalities of therapy. His current research focuses on identifying and therapeutically exploiting mechanisms employed by malignant cells to combat immune destruction. Prior to joining Georgetown Lombardi as director in 2008, Weiner served as chairman of the medical oncology department and vice president for translational research at Fox Chase Cancer Center in Philadelphia, PA, and served as professor in the department of medicine at Temple University School of Medicine. He is an active member of the American Society of Clinical Oncology and the American Association for Cancer Research (AACR) and founded the AACR Cancer Immunology Working Group. He has served as chair of the NCI Board of Scientific Counselors for clinical sciences and epidemiology and as a member of the NCI Clinical Trials Advisory Committee (CTAC). He also served on the NCI’s blue ribbon panel working group on immunotherapy for the National Cancer Moonshot Initiative and the Advisory Panel of the National Institutes of Health (NIH) Center for Scientific Research (CSR), which administers NIH research grants. He is recipient of the 2019 AACR Distinguished Public Service Award. Weiner earned his bachelor’s degree in biology with honors from the University of Pennsylvania and his M.D. from Mount Sinai School of Medicine. After completing his internship, residency, and service as chief medical resident at the University of Vermont’s Medical Center Hospital, he held clinical and research fellowships in hematology and oncology at Tufts University School of Medicine in Boston. 

Christopher M. Overall
Ph.D.

Canada Research Chair in Protease Proteomics and Systems Biology

The University of British Columbia

READ BIO

Christopher M. Overall
Ph.D.

Canada Research Chair in Protease Proteomics and Systems Biology

The University of British Columbia

Dr. Overall is a professor and Tier 1 Canada Research chair in proteinase proteomics and systems biology at the University of British Columbia, Centre for Blood Research. He completed his undergraduate in science with honors and master’s degrees at the University of Adelaide, South Australia; his Ph.D. in Biochemistry at the University of Toronto; and was an MRC Centennial Fellow in his post-doctoral work with Dr. Michael Smith, Nobel Laureate, Biotechnology Laboratory at the University of British Columbia (UBC). He was a visiting senior scientist at British Biotech Pharmaceuticals, Oxford, UK while on sabbatical in 1997 and 1998, and in 2004 and 2008 he was a visiting senior scientist at the Expert Protease Platform, Novartis Pharmaceuticals in Basel, Switzerland. At the Freiburg Institute for Advanced Studies at Albert-Ludwigs Universität in Freiburg, Germany he was an external senior fellow, and in November 2014 was appointed as an honorary professor at Albert-Ludwigs-Universität in Freiburg. Dr. Overall was awarded the Institute of Musculoskeletal Health and Arthritis CIHR Award as 2002 CIHR Scientist of the Year, the UBC Killam Senior Researcher Award (science) in 2005, and was the chair of both the 2003 Matrix Metalloproteinase Gordon Research Conference and the 2010 Protease Gordon Research Conference. He was elected to the HUPO Council and to the executive committee of the Chromosome–Centric Human Proteome Project (CHPP) in 2014. With over 15,571 citations for his 227 papers (since 2000 his papers have been cited more than 11,454 times) and with an h factor of 65 he is a highly influential scientist in the field. Professor Overall is also the pioneer of degradomics, a term he coined. With 23 papers published in Nature Review, Nature Journal, Cell Journal, Science and Science Signaling, he is a leader in the field. This leadership was most recently recognized by the International Society of Proteolysis with a Lifetime Achievement Award in 2011, by the Matrix Biology Society of Australia and New Zealand with the Barry Preston Award in 2012, by the IADR Distinguished Scientist Award for Research in Oral Biology in 2013; and by the Tony Pawson Canadian National Proteomics Network Award for Outstanding Contribution and Leadership to the Canadian Proteomics Community in 2014. He is an associate editor of the Journal of Proteomics, on the editorial boards of the Journal of Molecular Cellular Proteomics and Biological Chemistry and on the advisory committee of the International Union of Basic and Clinical Pharmacology.

"No one can change the world in a day, but we can all influence everyone we come in contact with to have a brighter day with a hello and a smile."

—CytomX Employee